InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes
The company’s new facilities add a large footprint of state-of-the-art laboratories and office space for scaling up InterVenn’s software development, technical support, clinical research and business development.
Nature’s Toolbox, Inc. to Present at the 2022 NIIMBL National Meeting
Nathan Duval, PhD, Lead Scientist, will present at the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) National Meeting
BioFlyte Welcomes New CEO to Drive Commercialization Efforts
Following its Series A financing, BioFlyte welcomes national security and public safety executive Todd Sickles as CEO to accelerate productization and market penetration of its disruptive biodetection technology
Aspinity AML100 Solution Delivers Industry’s Best Battery Life/Accuracy Combo for Glass Break Sensors
Aspinity’s power-intelligent analogML solution named 2022 Best of Sensors Awards finalist
Fluent BioSciences and NanoCellect announce joint collaboration to improve resolution of single-cell RNA sequencing analysis of rare cell populations
Fluent and NanoCellect are able to leverage and combine the unique advantages of our respective technologies to expand the use of single-cell RNA sequencing for rare cell populations.
XENDEE Raises $12M Series A Financing to Accelerate Deployments of Net-Zero Distributed Energy Systems and Ultra-Fast EV Charging Infrastructure
A strong list of investors including TravelCenters of America Inc., Evergy Ventures, and Anzu Partners joined the oversubscribed $12M round
Nature’s Toolbox, Inc. to Participate in the 2022 BIO International Convention
Several of NTx executives will attend the Biotechnology Innovation Organization (BIO) International Convention taking place at the San Diego Convention Center
Arduino Empowers Gen Z to Transform the Enterprise World
With $32 Million in New Capital from Robert Bosch Venture Capital, Renesas, Anzu Partners and Arm, Arduino’s Vision for Universal Innovation Moves from the Garage and Classroom to the Enterprise With New Professional Offerings
InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies
Networks will be instrumental in reaching patients and caregivers, making them aware of our platform and realizing its potential
InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients
DAWN™ IO Melanoma is commercially available as a unique glycoproteomics laboratory-developed test (LDT) that aids Oncologists in planning treatment for Melanoma